Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
615 Results for "
Ligand binding
" in MedChemExpress (MCE) Product Catalog:
Products (615)
615 Results for "Ligand binding" in MCE Product Catalog:
Cat. No.: HY-P86801
Synonyms: C C motif chemokine 3 antibody; CCL 3 antibody; CCL3 antibody; CCL3_HUMAN antibody; Chemokine (C C motif) Ligand 3 antibody; Chemokine C C motif Ligand 3 antibody; Chemokine Ligand 3 antibody; G0/G1 switch regulatory protein 19 1 antibody; G0/G1 switch regulatory protein 19-1 antibody; G0S19 1 antibody; C C motif chemokine 3 antibody; CCL 3 antibody; CCL3 antibody; CCL3_HUMAN antibody; Chemokine (C C motif) Ligand 3 antibody; Chemokine C C motif Ligand 3 antibody; Chemokine Ligand 3 antibody; G0/G1 switch regulatory protein 19 1 antibody; G0/G1 switch regulatory protein 19-1 antibody; G0S19 1 antibody; G0S19 1 protein antibody; Heparin binding chemotaxis protein antibody; L2G25B antibody; LD78 alpha antibody; LD78-alpha(4-69) antibody; LD78alpha antibody; Macrophage inflammatory protein 1 alpha antibody; Macrophage inflammatory protein 1-alpha antibody; macrophage inflammatory protein 1a antibody; M; IP : 1 alpha antibody; M; IP : 1A antibody; MIP-1-alpha antibody; MIP-1-alpha(4-69) antibody; MIP1 alpha antibody; MIP1A antibody; PAT 464.1 antibody; SCYA 3 antibody; SCYA3 antibody; SIS alpha antibody; SIS beta antibody; SIS-beta antibody; Small inducible cytokine A3 antibody; small inducible cytokine A3 (homologous to mouse Mip-1a) antibody; Small-inducible cytokine A3 antibody; Tonsillar lymphocyte LD78 alpha protein antibody;
Cat. No.: HY-119202
CAS No.: 357263-14-0
Synonyms: (S)-BMS-806
(S)-BMS-378806 ((S)-BMS-806) is an orally bioavailable HIV-1 inhibitor with activity against gp120-CD4 interactions. (S)-BMS-378806 exhibits micromolar inhibition of HIV-1 gp120-CD4 binding. The design and synthesis of (S)-BMS-378806 was based on a comprehensive study of protein-ligand interactions, which guided the identification and design of novel symmetrical N,N'-disubstituted aminoureas and thioureas. (S)-BMS-378806, synthesized in aqueous media using microwave irradiation, was validated for its inhibitory activity in HIV-1 gp120-CD4 capture ELISA .
Cat. No.: HY-183593
CAS No.: 3027375-00-1
Target:
Research Areas:
SHIP1-IN-1 is an orally active, blood-brain barrier-permeable SHIP1 ligand. SHIP1-IN-1 exhibits IC50 values of 384 μM and 177 μM against human SHIP1, and an IC50 value of 379 μM against murine SHIP1. SHIP1-IN-1 alters the binding state of SHIP1 to phosphatidylinositol membranes, and regulates phosphoinositide pools and phosphorylated AKT levels. SHIP1-IN-1 enhances the uptake of myelin/membrane fragments and amyloid proteins by microglia, alters gene expression and reduces IL-1β levels. SHIP1-IN-1 can be used in studies related to Alzheimer's disease .
Cat. No.: HY-189243
Target:
Research Areas:
P2Y2R antagonist-2 is an antagonist of the P2Y2 receptor (P2Y2R), with a pKi value of 6.53 for human P2Y2R. P2Y2R antagonist-2 blocks UTPγS (HY-137603)-induced calcium mobilization, binds to the orthosteric site of P2Y2R to displace fluorescent antagonist ligands, and forms unique binding interactions. P2Y2R antagonist-2 has no structural alerts, exhibiting low lipophilicity and high lipophilic efficiency. P2Y2R antagonist-2 can be used in studies related to astrocytoma and inflammation .
Cat. No.: HY-400882
CAS No.: 958233-17-5
Target:
Research Areas:
Tosylate-DPA-714 is a GMP-grade precursor for the radiosynthesis of DPA-714 (HY-122607). It crosses the blood-brain barrier and exhibits steroidogenic activity. DPA-714 is a specific ligand for the 18 kDa translocator protein (TSPO) with a Ki of 7.0 nM. Tosylate-DPA-714 is safe and does not bind to central benzodiazepine receptors (benzodiazepine receptor). As a radiolabeling precursor, Tosylate-DPA-714 reacts with 18F via nucleophilic aliphatic substitution to form 18F-DPA-714, enabling specific targeted binding to TSPO. 18F-DPA-714 accurately reflects the level of neuroinflammation mediated by microglial activation, and is used for PET molecular imaging of neurological diseases such as Alzheimer's disease and multiple sclerosis .
Cat. No.: HY-P10495
CAS No.: 1778685-49-6
Target:
Cat. No.: HY-P990857
Target:
Research Areas:
Cat. No.: HY-P991754
Target:
Research Areas:
Anti-Mouse TREM2 Antibody (178) is an antibody targeting mouse TREM2, which blocks the binding of ligands to TREM2 and inhibits TREM2-mediated signaling pathways. Anti-Mouse TREM2 Antibody (178) inhibits the tumor growth of MCA/1956 sarcoma in mice. Anti-Mouse TREM2 Antibody (178) enhances IFNγ production by intratumoral CD8 + T cells and TNFα production by intratumoral CD4 + T cells. Anti-Mouse TREM2 Antibody (178) can be used in the research of sarcoma, colorectal cancer and breast tumors. The recommended isotype control is Rat IgG2a kappa, Isotype Control (HY-P990679) .
Cat. No.: HY-P991944
Cat. No.: HY-P992454
Cat. No.: HY-E70699
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/T790M/C797S protein that can be used to study EGFR d746-750/T790M/C797S-related functions .
Cat. No.: HY-W004588
CAS No.: 72914-19-3
tBu2bpy is a bidentate nitrogen ligand that coordinates with Pt (II) and Pt (IV) to form functional complexes. The tBu2bpy Pt (II) bis-crown ether complex selectively recognizes Mg 2+ and Zn 2+; both ions significantly enhance the fluorescence of the complex and cause a blue shift of the absorption peak. Its six-coordinate Pt (IV) complex [Pt (X)2Me2 ( tBu2bpy)] inhibits the proliferation of tumor cells. tBu2bpy Pt (IV) complexes bind to DNA through multiple interactions including partial intercalation, groove binding, and electrostatic interaction, and can competitively displace ethidium bromide and covalently bind to purine nucleotides. tBu2bpy can be used in relevant research in fields such as organic synthesis .
Cat. No.: HY-120247
CAS No.: 1520893-08-6
Target:
Research Areas:
TASP0434299 (Compound 10) is a labeled ligand for the vasopressin V1b receptor. TASP0434299 exhibits high binding affinity for human and murine V1B receptors, with IC50 values of 0.526 nM and 0.641 nM, respectively, and shows potent antagonistic activity against the human V1B receptor with an IC50 of 0.639 nM. TASP0434299 is a substrate for human and rhesus monkey P-glycoprotein, resulting in low brain uptake in rhesus monkeys. TASP0434299 binds to V1B receptors in rat and monkey pituitary tissues in a saturable and specific manner both in vitro and in vivo. When radiolabeled with tritium or 11C, TASP0434299 serves as a prototype V1B receptor radiotracer to visualize V1B receptor in the pituitary gland of anesthetized monkeys via positron emission tomography .
Cat. No.: HY-148611
CAS No.: 1135037-53-4
Target:
Research Areas:
NSC339614 potassium is a selective GluN1/GluN2C and GluN1/GluN2D receptor enhancer with the activity of enhancing neuronal responses to specific NMDA receptors. NSC339614 potassium can selectively enhance the signaling of GluN1/GluN2C and GluN1/GluN2D receptors without affecting other NMDA receptors. The mechanism of action of NSC339614 potassium does not compete with agonists of L-glutamate or glycine, nor does it depend on membrane potential. The activity of NSC339614 potassium depends on the specific structure of the agonist ligand binding domain, showing its potential as a novel pharmacological agent for studying the function of NMDA receptor subtypes and providing new lead compounds for a variety of neurological diseases .
Cat. No.: HY-159922
Target:
Research Areas:
AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC50 value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC50 = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against ARF876L/T877A and ARW741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .
Cat. No.: HY-178938
CAS No.: 1182011-65-9
Research Areas:
AR Degrader-3 is an orally active molecular glue that targets AR/ARV7 and induces the degradation of AR and ARV7 through the ubiquitin-proteasome pathway (UPP). AR Degrader-3 directly interacts with the ligand-binding domain (LBD) and the N-terminal domain (NTD) of AR. AR Degrader-3 effectively suppresses the transcriptional activity of wild-type AR (AR-WT), AR mutants, and ARV7. AR Degrader-3 downregulates the mRNA and protein levels of downstream AR target genes, thereby overcoming antiandrogen resistance mediated by ARV7 and AR point mutations. AR Degrader-3 induces apoptosis in Enzalutamide (HY-70002) (ENZa)-resistant cells and increases cleaved caspase-3 protein levels. AR Degrader-3 can be used for the study of castration-resistant prostate cancer (CRPC) .
Cat. No.: HY-D3080
Target:
Research Areas:
CR-1 is a ratiometric photoacoustic (PA) probe for in-situ real-time imaging of Zn 2+ in deep living tissues. CR-1 is formed by coupling the near-infrared cyanine dye IR825 with the Zn 2+ ligand tris (2-pyridylmethyl) amine (TMPA). Upon binding to Zn 2+, the five N atoms on TMPA coordinate with Zn 2+, leading to double bond rearrangement of IR825 and attenuation of its π-electron conjugated system. The absorption peak of CR-1 blue-shifts from 710 nm to 532 nm, enabling quantitative detection of Zn 2+ via the PA532/PA710 ratio. Free CR-1 generates a strong PA signal at 710 nm, while CR-1 bound to Zn 2+ produces a strong PA signal at 532 nm .
Cat. No.: HY-P11642
CAS No.: 131748-26-0
Research Areas:
Cat. No.: HY-P991193
Target:
Research Areas:
Cat. No.: HY-P991641
Synonyms: LY3012218
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
